Synced daily from ClinicalTrials.gov via AACT. Last sync: .
13 Leronlimab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 10 indications (including Coronavirus Disease 2019 & COVID-19 Pneumonia) and 1,753 total planned enrollment. 2 Phase 3 Leronlimab trials and 8 Phase 2 are listed. 1 Leronlimab clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT06699836 (Mar 2028).
Where to Participate: All Leronlimab Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting Leronlimabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
State
Facility
City
Trial
Map
NY
Weill Cornell Medicine Brain Health Imaging Institute
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
NCT05730673withdrawnLeronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
NCT04901689suspendedLeronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
NCT04901676suspendedLeronlimab in Moderately Ill Patients With COVID-19 Pneumonia
NCT03838367terminatedLeronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
All Leronlimab trials (13)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
13 Leronlimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 5 are marked completed.
Are Leronlimab clinical trials recruiting in 2026?
Yes — 1 Leronlimab trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
What conditions is Leronlimab being studied for?
Leronlimab is being studied for Coronavirus Disease 2019, COVID-19 Pneumonia, Colorectal Cancer, Metastatic, Metastatic Colorectal Cancer (mCRC) and 11 more. The trials are grouped by indication on this page.
What phase is Leronlimab in?
Leronlimab clinical trials span 2 Phase 3, 8 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Leronlimab clinical trials?
The lead sponsor across the most Leronlimab trials is CytoDyn, Inc., with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Leronlimabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.